Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$41.88
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
SWOT Analysis — HROW
Inflationary BoomStrengths
Operating Cash Flow: $43.9M (+297.6% YoY) — Operating cash flow grew 298% — the business generated more cash from day-to-day operations.
EPS (Diluted): $-0.14 (+71.4% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Net Income: -$5.1M (+70.6% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Revenue: $272.3M (+36.4% YoY) — Revenue grew 36% — the company sold more goods or services than the prior year.
Gross Profit: $204.4M (+35.9% YoY) — Gross profit rose 36% — the spread between revenue and direct costs improved.
Weaknesses
No material weaknesses flagged.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $5.1M — the company spent more than it earned. Investors should monitor the path to profitability.
Total liabilities are 87% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Financial Charts
Year-over-Year Changes
Operating Cash Flow
$43.9M
was -$22.2M
Operating cash flow grew 298% — the business generated more cash from day-to-day operations.
EPS (Diluted)
$-0.14
was $-0.49
Negative EPS — the company recorded a loss on a per-share basis.
Net Income
-$5.1M
was -$17.5M
The company posted a net loss — total expenses exceeded total revenue.
Revenue
$272.3M
was $199.6M
Revenue grew 36% — the company sold more goods or services than the prior year.
Gross Profit
$204.4M
was $150.4M
Gross profit rose 36% — the spread between revenue and direct costs improved.
Risk Flags
2 high · 0 medium · 0 low- ⚠ High
Net loss of $5.1M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Total liabilities are 87% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade HROW
Links open broker research pages. Not an endorsement or recommendation.
Research Harrow, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.